AL

Alumis Inc. Common Stock

ALMS · Nasdaq

Alumis Inc. Common Stock (ALMS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Alumis Inc. Common Stock in 2026. The next earnings report is expected on November 12, 2026.

Earnings calendar

Next earnings date

12 Nov 2026

In 85 days

EPS estimate

-0.75

Revenue estimate

1.9M

Past earnings

13 Aug 2026
EPS actual
-1.11 (-16.5%)
estimate -0.95
Revenue actual
1.7M (-48.2%)
estimate 3.2M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
14 May 2026
EPS actual
-0.74 (-1.1%)
estimate -0.73
Revenue actual
1.7M (-17.2%)
estimate 2.1M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
19 Mar 2026
EPS actual
-0.88 (+4.6%)
estimate -0.92
Revenue actual
1.9M (-18.4%)
estimate 2.4M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
13 Nov 2025
EPS actual
-1.06 (-13.7%)
estimate -0.93
Revenue actual
2.1M (-34.8%)
estimate 3.2M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Alumis Inc. Common Stock missed consensus estimates in its latest earnings report, with EPS of -$1.11 versus an expected -$0.9532 and revenue of $1.66 million that fell 48.2% short of the $3.21 million consensus. In the previous report, both EPS and revenue also came in below expectations.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Martin Babler
Employees
168
IPO date
22 Feb 2021
ISIN
US0223071020
Website
alumis.com

Frequently asked questions

When does Alumis Inc. Common Stock (ALMS) next report earnings?

Alumis Inc. Common Stock (ALMS) is scheduled to report earnings on November 12, 2026.

What was Alumis Inc. Common Stock's most recent earnings date?

Alumis Inc. Common Stock (ALMS) last reported earnings on August 13, 2026.

Where is Alumis Inc. Common Stock stock listed?

Alumis Inc. Common Stock (ALMS) is listed on Nasdaq.